Save Big this SUMMER. SAME PRICE EVERY MONTH! STARTING at GLP-1: $79 | GLP-1 + GIP: $125. OFFER ENDS AUGUST 5TH AT MIDNIGHT!

Privacy Policy

Our Notice of Privacy Practices is a separate document that governs how protected health information (PHI) about you may be used and disclosed in accordance with HIPAA.

I. Introduction

This Privacy Policy describes how Trinity Healthcare Supply, LLC d.b.a. Next Meds ("Next Meds"), in partnership with OpenLoop Health, Inc. and its affiliated medical groups and providers, collects and uses Personal Data about you.

Next Meds respects your privacy, and we are committed to protecting it through our compliance with this policy.

II. Information We Collect

We collect: personally identifiable information (name, address, email, phone), health-related information, internet/device information, and usage details.

We collect information directly from you, automatically as you navigate the Platform, and from third parties such as physicians and pharmacies.

The Platform may utilize cookies to improve functionality. You can set your browser to refuse cookies. We respond to Global Privacy Control (GPC) signals.

III. How We Use Your Information

We use your information for treatment, payment, healthcare operations, communications, account administration, platform improvement, fraud prevention, legal compliance, and AI/machine learning analysis in compliance with HIPAA.

SMS/Text Messaging

If you opt in to receive texts from Next Meds/OpenLoop, you consent to recurring SMS/MMS messages. Reply STOP to unsubscribe. Consent is not a condition of purchase.

IV. Disclosure of Information

We may disclose your information to service providers, medical providers, OpenLoop affiliates, payment processors, marketing entities, and as required by law.

No mobile information will be shared with third parties/affiliates for marketing/promotional purposes.

V. Your Options

You can refuse cookies via your browser. We do not currently respond to 'do not track' signals.

VI. Data Security

We implement reasonable security measures. In the event of a breach, we will notify you within 60 days as required by law.

VII. Third-Party Platforms

Our Platform may link to third-party websites. Next Meds and OpenLoop are not responsible for third-party privacy practices.

VIII. Minimum Age

Next Meds does not knowingly provide services to minors under 18.

IX. California Privacy Rights (CCPA)

You have the right to know about the Personal Information we collect, use, and disclose about you in the past 12 months.

You have the right to request that we delete the Personal Information we collect about you.

We do not discriminate against you for exercising any of your privacy rights.

For Right to Know and Right to Deletion requests, write to the Compliance Officer or email care@nextmeds.com.

X. Revisions

We reserve the right to change this Privacy Policy at any time. Your continued use of the Platform constitutes acceptance of changes.

XI. Contact

Next Meds, Inc., 8 The Green, Suite A, Dover, DE 19901
Email: care@nextmeds.com
Phone: +1 855-739-9995

Next Meds

*The assessment made available on the Next Meds website does not create a doctor-patient relationship between the individual completing the assessment and Next Meds. OpenLoop Health, a network of US-licensed doctors that adhere to rigorous medical protocols designed for patient safety, has established exclusionary criteria to determine if an individual does not qualify for GLP-1s. The answers an individual provides to the Next Meds assessment consequently determine if the individual is screened out of eligibility for GLP-1 medication, and a OpenLoop Health clinician will meet with an individual after checkout to determine if they qualify for a prescription. OpenLoop Health clinicians retain the decision to prescribe compounded GLP-1s to patients.

All claims and benefits on this website refer to self-reported data from GLP-1 customers on a treatment plan that includes compounded GLP-1 medications and consultations with medical professionals. Customers reported their weight on their initial medical intake questionnaire every 3-4 weeks thereafter. Results from compounded medications found on the Next Meds platform may vary and be affected by an individual's adherence to the program and their clinician's recommendations. Compounded GLP-1s are produced in FDA-regulated facilities. Although these facilities are highly regulated, the medications are not FDA-approved or evaluated for safety, efficacy, or quality. The decision to use compounded drugs is guided by the licensed provider's medical judgment, which is informed by a telehealth consultation and medical history. We encourage all prospective users of compounded medications to speak with their provider about the specific risks and benefits that may come with the use of compounded medication. Next Meds does not produce compounded medications, and individuals may receive medication that looks different than what is portrayed on the website.

Pharmacy Providers: We are partnered with multiple USA certified pharmacies to bring the best product and overall experience to our membership. Our team meets regularly with pharmacies to discuss any product shortages, shipping delays, and get updated reports on their medication testing.

*Results vary based on starting weight and program adherence. Inches lost from hips, waist, chest, thighs and arms in the first month. Patients exercised daily and ate a reduced-calorie diet. Their fat loss is not typical. Results may vary. Medication prescriptions are at the discretion of medical providers and may not be suitable for everyone. Next Meds patients typically result in 1-2 lbs per week weight loss after 4 weeks, involving a healthy diet and exercise changes. Consult a healthcare professional before using medication or starting any weight loss program. *Based on the average weight loss as reported by patients without diabetes who reached and maintained a dose of 2.4 mg/week of GLP-1 treatment, along with a reduced-calorie diet and increased physical activity.

Medication is included in the cost of the Next Meds Program. Wegovy® is FDA-approved for weight loss. Ozempic® is FDA-approved for type 2 diabetes treatment but may be prescribed for weight loss. The trademarks, service marks, trade names (Wegovy®, Ozempic®), and products displayed on this Internet site are protected and belong to their respective owners. Medical treatment is provided by “OpenLoop Affiliated P.C.s,” and OpenLoop Health, affiliated networks for medical professional corporations and associations. No data, photos, claims or any other information is associated with results derived from clinical trials, studies or public information and is always representative of Next Meds patient experience.

For support: care@nextmeds.com  |  +1 855-739-9995

All medical services, including clinical evaluations, treatment planning, and prescribing decisions are provided by affiliated professional medical practices, which are independently owned and operated. Trinity HealthCare Supply, LLC d/b/a Next Meds provides the technology platform and administrative coordination services that connect you with your healthcare provider. Next Meds does not provide medical services, does not employ healthcare providers, does not participate in clinical decisions, and does not practice medicine.

Verify Approval for www.nextmeds.com

© 2026 NextMeds. All rights reserved.